Figure 1. The BET inhibitor JQ1 substantially decreases the viability of patient-derived CTCL cells and CTCL cell lines.

All samples were incubated with JQ1 for 72 hours and dose-response curves were generated, from which IC₅₀ and hill slopes were calculated. (A) IC₅₀ of patient-derived samples in increasing order. The median and mean IC₅₀s were 4.29 µM and 6.05 µM, respectively. Mycosis fungoides (MF) patients are in blue and Sézary syndrome (SS) patients are in red. (B) Comparison of IC₅₀ with CTCL subtype at the time of diagnosis as either MF or SS. (C) Comparison of IC₅₀ with CTCL B stage based on ISCL classification. (D) Representative dose-response curves for patient-derived samples. (E) Dose-response curves for cell lines. (F) Comparison of IC₅₀ with MYC amplification status in patient-derived samples. (G) Comparison of IC₅₀ with MYC amplification status in cell lines. ns, p > 0.05; pt, patient; ^*p < 0.05.